The effect of LCZ696 (sacubitril/valsartan) on amyloid‐β concentrations in cerebrospinal fluid in healthy subjects-Reference-Cited by-同舟云学术

The effect of LCZ696 (sacubitril/valsartan) on amyloid‐β concentrations in cerebrospinal fluid in healthy subjects

Published:2016-03-08 Issue:5 Volume:81 Page:878-890
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Langenickel Thomas H.¹,Tsubouchi Chiaki¹,Ayalasomayajula Surya²,Pal Parasar³,Valentin Marie‐Anne¹,Hinder Markus¹,Jhee Stanford⁴,Gevorkyan Hakop⁵,Rajman Iris¹

Affiliation:

1. Translational Medicine, Novartis Institutes for Biomedical Research Novartis Pharma AG Basel Switzerland

2. Drug Metabolism and Pharmacokinetics Novartis Institutes for Biomedical Research East Hanover New Jersey USA

3. Biostatistical Sciences, Integrated Development Functions and Regions Novartis Healthcare Pvt Ltd Hyderabad India

4. PAREXEL International Glendale California USA

5. California Clinical Trials Medical Group in Affiliation with PAREXEL International Glendale California USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.12861

Reference39 articles.

1. Angiotensin receptor-neprilysin inhibition with LCZ696: a novel approach for the treatment of heart failure

2. Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure

3. Combined Neprilysin and Renin-Angiotensin System Inhibition for the Treatment of Heart Failure

4. Trafficking and Proteolytic Processing of APP

5. Proteolytic Degradation of Amyloid -Protein

Cited by 92 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association between treatment with sacubitril/valsartan and the risk of Alzheimer’s disease: a clinical update;Alzheimer's Research & Therapy;2024-08-01

2. Effect of Sacubitril/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A Prespecified Analysis of PARAGON-HF;Circulation;2024-07-23

3. Alzheimer disease blood biomarkers: considerations for population-level use;Nature Reviews Neurology;2024-06-11

4. Safety of cardiovascular disease drugs approved between 2014 and 2021 in the US: a pharmacovigilance analysis;Expert Review of Cardiovascular Therapy;2024-05-12

5. Effect of Neprilysin Inhibition on Alzheimer Disease Plasma Biomarkers;JAMA Neurology;2023-12-18